Randomised clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids

British Journal of Surgery

Volumn 87, Issue 7, 2000, Pages 868-872

  Misra, M C ^a,b   Parshad, R ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MAFRAQ HOSPITAL   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

DAFLON; DIOSMIN; FLAVONOID; HESPERIDIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEMORRHOID; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ACUTE DISEASE; AMBULATORY CARE;

ACUTE DISEASE; ADULT; AMBULATORY CARE; DOUBLE-BLIND METHOD; FEMALE; FLAVONOIDS; GASTROINTESTINAL HEMORRHAGE; HEMORRHOIDS; HUMANS; MALE; RECURRENCE; TREATMENT OUTCOME;

EID: 0033624257     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2000.01448.x     Document Type: Article

References (16)

1. 1 Hancock BD. ABC of colorectal diseases. Haemorrhoids. BMJ 1992; 304: 1042-4.
2. 2 Hardwick RH, Durdey P. Should rubber band ligation of haemorrhoids be performed at the initial outpatient visit? Ann R Coll Surg Engl 1994; 76: 185-7.
3. 3 Haas PA, Fox TA Jr, Haas GP. The pathogenesis of hemorrhoids. Dis Colon Rectum 1984; 27: 442-50.
4. 4 Labrid C, Duhault J. Pharmacologic properties of Daflon 500 mg. Int J Med 1987; 85(Suppl): 30-5.
5. 5 Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994; 45: 566-73.
6. 6 Godeberge PH. Daflon 500 mg is significantly more effective than placebo in the treatment of haemorrhoids. Phlebology 1992; 7(Suppl 2): 61-3.
7. 7 Cospite M, Cospite V. Treatment of haemorrhoids with Daflon 500 mg. Phlebology 1992; 7(Suppl 2): 53-6.
8. 8 Buckshee K, Takkar D, Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynaecol Obstet 1997; 57: 145-51.
9. 9 Delmout J, Ljunggren B, De Champvallins M, Granger C. Assessment of the acceptability and efficacy of Daflon 500 mg in the long term treatment (6 months) of haemorrhoids. International Journal of Clinical Practice 1992; 8: 14-18.
10. 10 Lawrence MB, McIntire LV, Eskin SG. Effect of flow on polymorphonuclear/endothelial cell adhesion. Blood 1987; 70: 1284-90.
11. 11 Weissmann G, Smolen JE, Korchak HM. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med 1980; 303: 27-34.
12. 12 Shami SK, Shields DA, Scurr JH, Coleridge Smith PD. Leg ulceration in venous disease. Postgrad Med J 1992; 68: 779-85.
13. 13 Barbe R, Amiel M. Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg. Phlebology 1992; 7(Suppl 2): 41-4.
14. 14 Cotonat A, Cotonat J. Lymphogogue and pulsatile activities of Daflon 500 mg on canine thoracic lymph duct. Int Angiol 1989; 8(Suppl 4): 15-18.
15. 99m red cells. Application to pharmacodynamic activity of Daflon 500 mg. Int Angiol 1988; 7(Suppl 2): 35-8.
16. 16 Galley P. Study of activity of Daflon 500 mg on capillary resistance. Int J Med 1987; 88(Suppl): 25-6.